Logo
x

Search

Subscribe Now

All Posts by Date

PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma

PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Mult...

  • May 2, 2022
Sage and Biogen Initiate Rolling Submission of NDA to US FDA for Zuranolone to Treat Major Depressive Disorder

Sage and Biogen Initiate Rolling Submission of NDA to US FDA for Zuranolone to Treat Major Depressive Disorder

  • May 2, 2022
CytoSorbents Reports the First Patient Enrollment of DrugSorb-ATR Antithrombotic Removal System in the (STAR-D) Trial During Cardiac Surgery

CytoSorbents Reports the First Patient Enrollment of DrugSorb-ATR Antithrombotic Removal System in the (STAR-D) Trial During Cardi...

  • May 2, 2022
Abbott Reports Results of TactiCath SE in (PERSIST-END) Study for the Treatment of Persistent Atrial Fibrillation

Abbott Reports Results of TactiCath SE in (PERSIST-END) Study for the Treatment of Persistent Atrial Fibrillation

  • May 2, 2022
Horizon’s Uplizna (inebilizumab) Receives EC’s Approval for the Treatment of Neuromyelitis Optica Spectrum Disorder

Horizon’s Uplizna (inebilizumab) Receives EC’s Approval for the Treatment of Neuromyelitis Optica Spectrum Disorder

  • May 2, 2022
Merck’s Keytruda (pembrolizumab) Receives EC’s Approval for MSI-H or dMMR Tumors in Five Different Types of Cancer

Merck’s Keytruda (pembrolizumab) Receives EC’s Approval for MSI-H or dMMR Tumors in Five Different Types of Cancer

  • May 2, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.